Psyence Biomedical Ltd.
PBM
$3.48
-$0.08-2.25%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -785.55% | 76.13% | 91.54% | 97.00% | 101.98% |
| Total Depreciation and Amortization | 23.81% | 64.52% | 150.00% | 318.18% | 2,000.00% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 100.10% | -99.86% | -99.88% | -104.58% | -108.84% |
| Change in Net Operating Assets | -214.91% | -10.84% | 64.92% | 66.06% | 67.08% |
| Cash from Operations | -118.07% | -87.53% | -47.85% | -37.18% | -26.78% |
| Capital Expenditure | 97.96% | 82.73% | 70.49% | 25.56% | -68.97% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -70,387.50% | -133,162.50% | -- | -- | -- |
| Cash from Investing | -27,748.15% | -29,944.37% | -32,860.66% | -22,330.00% | -179.31% |
| Total Debt Issued | -- | -100.00% | -100.00% | -81.08% | -60.00% |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | 0.00% | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 117.83% | 221.85% | 644.62% | 1,051.07% | -- |
| Cash from Financing | 52.57% | 105.39% | 220.17% | 244.98% | 289.46% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -75.76% | -3.00% | 293.11% | 1,362.32% | 998.84% |